MARKET

KYTX

KYTX

Kyverna Therapeutics
NASDAQ
10.78
+0.55
+5.38%
Pre Market: 10.76 -0.02 -0.19% 06:12 05/14 EDT
OPEN
10.29
PREV CLOSE
10.23
HIGH
11.15
LOW
10.27
VOLUME
51
TURNOVER
0
52 WEEK HIGH
13.67
52 WEEK LOW
2.060
MARKET CAP
652.52M
P/E (TTM)
-2.9579
1D
5D
1M
3M
1Y
5Y
1D
Kyverna Therapeutics Price Target Cut to $29.00/Share From $30.00 by JP Morgan
Dow Jones · 18h ago
Kyverna Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 18h ago
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29
Benzinga · 18h ago
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medicine, Inc. (PRME)
TipRanks · 20h ago
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
TipRanks · 23h ago
Wells Fargo Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)
TipRanks · 1d ago
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
TipRanks · 1d ago
Kyverna begins rolling BLA submission for miv-cel
Seeking Alpha · 1d ago
More
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Webull offers Kyverna Therapeutics Inc stock information, including NASDAQ: KYTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYTX stock methods without spending real money on the virtual paper trading platform.